

25. (Amended) After "accession number" please insert -- HB-12574 --.

26. (Amended) After "accession number" please insert -- HB-12572 --.

27. (Amended) After "accession number" please insert -- HB-12571 --.

28. (Amended) After "accession number" please insert -- HB-12575 --.

29. (Amended) After "accession number" please insert -- HB-12573 --.

30. (Amended) After "accession number" please insert -- HB-12574 --.

31. (Amended) After "accession number" please insert -- HB-12572 --.

32. (Amended) After "accession number" please insert -- HB-12571 --.

33. (Amended) After "accession number" please insert -- HB-12575 --.

34. (Amended) After "accession number" please insert -- HB-12573 --.

35. (Amended) After "accession number" please insert -- HB-12574 --.

36. (Amended) After "accession number" please insert -- HB-12572 --.

37. (Amended) After "accession number" please insert -- HB-12571 --.

38. (Amended) After "accession number" please insert -- HB-12575 --.

39. (Amended) After "accession number" please insert -- HB-12574 --.

55. (Amended) An article of manufacture, comprising a container and a composition contained within said container, wherein the composition includes [DcR3 polypeptide or] DcR3 antibodies of claim 14.

18
56. (Amended) The article of manufacture of claim 55 further comprising instructions for using the [DcR3 polypeptide or] DcR3 antibodies *in vivo* or *ex vivo*.

Please add the following claims:

--67. The antibody of claim 16 wherein said antibody blocks binding of Fas ligand to DcR3 polypeptide.

68. The antibody of claim 14 wherein said DcR3 polypeptide comprises amino acid residues 1 to 215 of Figure 1 (SEQ ID NO:1).

69. The antibody of claim 14 wherein said DcR3 polypeptide comprises amino acid residues 1 to 300 of Figure 1 (SEQ ID NO:1).

70. The antibody of claim 14 wherein said antibody binds to said DcR3 polypeptide but does not bind to DR4, DR5, DcR1 or OPG receptor polypeptides.

70. The antibody of claim 14 wherein said antibody is labeled with a molecule which produces a detectable signal.

71. The antibody of claim 70 wherein said molecule which produces a detectable signal is a radioisotope, fluorescent compound, chemiluminescent compound, or enzyme.

72. An isolated anti-DcR3 antibody which blocks binding of a ligand polypeptide to a DcR3 polypeptide comprising an amino acid sequence which has at least 80% sequence identity to amino acids 1 to 215 of Figure 1 (SEQ ID NO:1).

73. The antibody of claim 72 wherein said DcR3 polypeptide comprises amino acids 1 to 215 of Figure 1 (SEQ ID NO:1).

74. The antibody of claim 72 wherein said ligand polypeptide is a tumor necrosis factor-related cytokine.

75. The antibody of claim 74 wherein said ligand polypeptide is Fas ligand.

76. The antibody of claim 72 wherein said antibody is a monoclonal antibody.

77. The antibody of claim 72 wherein said antibody comprises a chimeric antibody.

78. The antibody of claim 72 wherein said antibody comprises a human antibody.

79. The antibody of claim 72 wherein said antibody comprises an antibody fragment.

80. An isolated anti-DcR3 antibody which neutralizes one or more activities of a DcR3 polypeptide comprising an amino acid sequence which has at least 80% sequence identity to amino acids 1 to 215 of Figure 1 (SEQ ID NO:1).

81. The antibody of claim 80 wherein said DcR3 polypeptide comprises amino acids 1 to 215 of Figure 1 (SEQ ID NO:1).

82. The antibody of claim 80 wherein said one or more activities of said DcR3 polypeptide is blocking of Fas ligand-induced apoptosis in a mammalian cell.

83. The antibody of claim 82 wherein said blocking activity of said DcR3 polypeptide inhibits or reduces Fas ligand-induced apoptosis of mammalian cancer cells.

84. The antibody of claim 82 wherein said mammalian cancer cells include colon cancer cells or lung cancer cells.

85. The antibody of claim 80 wherein said antibody is a monoclonal antibody.

86. The antibody of claim 80 wherein said antibody comprises a chimeric